{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-007867","form_type":"8-K","ticker":"IMCR","cik":"0001671927","company_name":"Immunocore Holdings plc","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.388331+00:00","generated_at":"2026-05-25T01:39:15.299940+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunocore HIV cure candidate IMC-M113V shows dose-dependent viral control in Phase 1/2 MAD data at CROI 2025","bullets":["Well tolerated across 60-300 mcg doses; no dose-limiting toxicities or serious AEs; mild CRS in 5 of 6 at 300 mcg.","3 of 15 evaluable PLWH showed delayed viral rebound or viremia control after ART interruption; 2 remained off ART for full 12 weeks.","Dose-dependent reduction in active reservoir (CD4+ Gag RNA) and trend of intact HIV DNA reduction at higher doses.","Enrollment continues with higher doses; expansion cohorts planned at one or more doses.","IMC-M113V is first TCR bispecific targeting HIV in clinic, aims for functional cure."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-007867","json":"https://secwatch.observer/filing/0001140361-25-007867.json","markdown":"https://secwatch.observer/filing/0001140361-25-007867.md","text":"https://secwatch.observer/filing/0001140361-25-007867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671927/000114036125007867/0001140361-25-007867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671927/000114036125007867/ef20045169_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T01:39:15.299940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}